Beads (2)Antibody (11)
Launched (13)
Mouse (13)
- (13)
- (2)Unconjugated (1)HRP Labeled (1)Acridinium ester Labeled (1)PE Labeled (2)FA Labeled (3)AF488 Labeled (1)Biotin-labeled (1)Europium chelate Labeled (1)
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Praluzatamab ravtansine | CX-2009 | Phase 2 Clinical | Immunogen Inc, Cytomx Therapeutics Inc | Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |



[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



